Imfinzi is approved in the EU to treat early-stage gastric and gastroesophageal cancers in combination with chemotherapy.

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter. It is a diversified fund that focuses on long-term capital appreciation by ...

AstraZeneca PLC (NYSE:AZN) is one of Goldman Sachs top healthcare stocks. On March 9, AstraZeneca PLC (NYSE:AZN) and Daiichi ...

Astrazeneca (AZN) closed the most recent trading day at $189.90, moving -1.35% from the previous trading session. The stock's performance was behind the S&P 500's daily loss of 0.61%. Meanwhile, the ...

AstraZeneca PLC is a leading global pharmaceutical company with strong growth in oncology, diversified revenues, and a robust pipeline. AZN's financials show improving margins, rising EPS, and ...

AstraZeneca AZN is scheduled to report fourth-quarter and full-year 2025 results on Feb. 10, before the opening bell. In the last reported quarter, the company delivered an earnings surprise of 4.39% ...

AstraZeneca, the U.K.-Swedish pharmaceutical giant, on Tuesday announced a plan to invest some $50 billion in the U.S. in a move hailed by the Trump administration - though much of what it is ...

AstraZeneca's shares jumped after Pfizer's announcement of a major deal with the Trump administration. Pfizer's good news could benefit AstraZeneca, too. 10 stocks we like better than AstraZeneca Plc ...

British drugmaker AstraZeneca Plc AZN has emerged as the leading contender to acquire French biotech Abivax SA ABVX, ...